Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Jaguar Health (NASDAQ:JAGX) plans to leverage AI platforms to support development, commercialization, and healthcare delivery for crofelemer in intestinal failure (IF) including pediatric MVID.

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) plans to leverage AI platforms to support development, commercialization, and healthcare delivery for crofelemer in intestinal failure (IF) including pediatric MVID.

Key points: an investigator-sponsored MVID program showed up to 37% reduction in parenteral support; Jaguar is pursuing Breakthrough Therapy designation and is seeking non-dilutive partner funding to accelerate approval and access.

Positive

• Parenteral support reduced by up to 37% in investigator-sponsored MVID treatment
• Pursuing Breakthrough Therapy designation to expedite FDA pathways
• AI platforms planned to generate real-world evidence linking genetics, histopathology, and outcomes

Negative

• Development progress contingent on securing non-dilutive partner funding
• MVID is ultrarare, creating small patient population challenges for commercialization

Argus Apr 13 session

+5.69% close to close 3.0x rel. volume Open Argus

Details

News Market Reaction – JAGX

On Apr 13, the day this news came out, JAGX closed 5.69% above the previous close. That session’s volume was 3.0x the stock’s average daily volume.

Data tracked by StockTitan Argus for the Apr 13 session.

Key Figures

SBS/IF market size: $8.0 billion Parenteral support reduction: 37%

SBS/IF market size

$8.0 billion

Global short bowel syndrome/intestinal failure market by 2033

Parenteral support reduction

37%

Investigator-sponsored MVID treatment program cited in IF development update

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Investor webcast notice

   24h Move

   -2.6%

   Reminder of webcast on Q4 2025 financials and company updates.

2. Apr 08

   Veterinary trial progress

   24h Move

   -2.6%

   Completion of Canalevia-CA1 effectiveness study and renewed conditional approval.

3. Apr 07

   2025 financial results

   24h Move

   -0.1%

   Higher operating losses despite net revenue and a $16.0M license payment.

4. Apr 02

   Conference and IF data

   24h Move

   -1.5%

   Ped-GI conference sponsorship and PS reductions of 12–37% in IF patients.

5. Mar 18

   Clinical trial extension

   24h Move

   -8.0%

   FDA-supported extension phase for crofelemer MVID trial to assess long-term benefit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intestinal failure, microvillus inclusion disease, orphan disease, parenteral support, +4 more

8 terms

intestinal failure medical

"crofelemer programs for the treatment of intestinal failure in both adult and pediatric"

Intestinal failure is a medical condition in which the gut cannot absorb enough nutrients, fluids, or electrolytes to keep a person healthy, so they need long‑term medical support such as intravenous nutrition or specialized feeding tubes. Think of the intestines as a conveyor belt that breaks down and delivers fuel to the body; when it fails, ongoing treatments, surgeries, and chronic care services become necessary. For investors, this creates steady demand for therapies, medical devices, home infusion services and related regulatory approvals that can drive revenue and long‑term contracts.

microvillus inclusion disease medical

"pediatric microvillus inclusion disease (MVID)Jaguar seeking efficiencies"

A rare, inherited condition in which the tiny, brush-like hairs on the inner lining of the small intestine are absent or abnormal, causing severe, lifelong diarrhea and inability to absorb nutrients. Think of the intestine’s surface as a shaggy carpet that helps soak up food; when those fibers are missing or disorganized, patients often need long-term intravenous feeding and specialized care. For investors, the disease matters because it creates clear demand for diagnostics, nutritional support, transplant solutions, and targeted therapies in the orphan-disease market.

orphan disease medical

"patients with orphan disease designated pediatric microvillus inclusion disease"

A rare medical condition that affects a very small number of people, often so few that standard drug development and commercial sales are impractical. For investors it matters because treatments for these conditions can qualify for special regulatory incentives, faster approval paths and price premiums, so a successful therapy is like owning a product that dominates a tiny but underserved niche market — high potential reward but also higher scientific and commercial risk.

parenteral support medical

"including the ground-breaking and consistent reduction of parenteral support of up to 37%"

Parenteral support is medical care that delivers nutrition, fluids or medications directly into a patient’s bloodstream or body tissues, bypassing the digestive system—think of it as feeding or hydrating someone through an IV rather than by mouth. Investors care because this service involves specialized products, durable revenue from long-term patient use, strict safety and reimbursement rules, and potential regulatory or supply risks that affect company earnings and growth.

breakthrough therapy designation regulatory

"plan for obtaining Breakthrough Therapy designation from the U.S. Food and Drug"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

fda approval regulatory

"bring crofelemer to FDA approval for MVID-a disease with no alternative"

FDA approval is the U.S. Food and Drug Administration’s formal authorization for a drug, vaccine, or medical device to be marketed and sold after reviewers determine it meets standards for safety and effectiveness. For investors it’s a pivotal milestone because it opens the door to legal, large-scale sales and can sharply boost revenue potential while reducing regulatory uncertainty—like receiving a safety certificate that lets a new bridge carry traffic and tolls.

real-world evidence technical

"include real-world evidence to support the effectiveness and benefit of new therapies"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

histopathology medical

"credible links between genetics, histopathology, and clinical manifestation"

Microscopic examination of tissue samples to identify disease, damage, or the effects of a treatment; pathologists slice, stain and study cells much like a mechanic inspects engine parts to find what’s broken. For investors, histopathology provides hard evidence about whether a drug, device or diagnostic actually works or causes harm, and those findings can strongly influence clinical outcomes, regulatory decisions and a company’s future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 2033¹

AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression modification for intestinal failure (IF) patients with orphan disease designated pediatric microvillus inclusion disease (MVID)

Jaguar seeking efficiencies to bring crofelemer to FDA approval for MVID-a disease with no alternative treatments and a lethal natural history

SAN FRANCISCO, CA / ACCESS Newswire / April 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it plans to use AI platforms to enhance its development, commercialization, and healthcare delivery objectives for crofelemer programs for the treatment of intestinal failure in both adult and pediatric patients.

"Our IF program in MVID could leverage AI platforms that could help guide personalized regimens for each patient for this ultrarare disease and include real-world evidence to support the effectiveness and benefit of new therapies like crofelemer in mitigating disease progression by potentially providing credible links between genetics, histopathology, and clinical manifestation. AI platforms could lead to more efficient drug development and quicker access to drugs for patients with no alternative treatments for diseases with lethal natural history, such as MVID." said Pravin Chaturvedi, PhD, Jaguar's Chief Scientific Officer and Chair of the Jaguar Scientific Advisory Board.

"We are strategically focused on demonstrating crofelemer's effectiveness and achieving faster commercialization to meet our healthcare delivery objectives for IF indications," said Lisa Conte, Jaguar's founder, president, and CEO. "Our IF development programs continue to make progress in meeting key clinical milestones, including the ground-breaking and consistent reduction of parenteral support of up to 37% in an investigator-sponsored MVID treatment program. We are currently in business development discussions with the goal of bringing in non-dilutive funds from potential partners. We are encouraged to report that our development plan for MVID could include a plan for obtaining Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in the coming months, which would augment expedited regulatory submission pathways for this pediatric disorder. The very low prevalence of MVID and its lethal natural history without any available therapies underscores the need for rapid and efficient development and commercialization of crofelemer. In addressing this very serious unmet medical need, and we are exploring AI platforms to assist in achieving our objectives."

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company may utilize AI to support its intestinal failure program, and Jaguar's expectation that its development plan for MVID may support the possibility for a Breakthrough Therapy designation from the FDA in the coming months, potentially supporting opportunities for expedited regulatory submission pathways to the FDA for new drug approval. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹Global Short Bowel Syndrome Market - Size, Share, and Forecast (2025-2033)

Contact:
hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Jaguar (JAGX) report crofelemer performed in the investigator-sponsored MVID program?

Jaguar reported a direct result of up to 37% reduction in parenteral support in an investigator-sponsored MVID treatment program. According to the company, this consistent reduction is a key clinical milestone supporting crofelemer's potential benefit in IF indications.

What does Jaguar say about using AI for crofelemer development (JAGX) on April 13, 2026?

Jaguar intends to use AI platforms to guide personalized regimens and real-world evidence for IF and MVID. According to the company, AI could link genetics, histopathology, and clinical manifestation to support drug development and commercialization.

Is Jaguar seeking an FDA Breakthrough Therapy designation for crofelemer (JAGX)?

Yes, Jaguar said it could include a plan to pursue Breakthrough Therapy designation for MVID in the coming months. According to the company, that designation would augment expedited regulatory submission pathways if granted.

How is Jaguar (JAGX) planning to fund further crofelemer development for IF indications?

Jaguar is in business development discussions aiming to bring in non-dilutive funds from potential partners. According to the company, these partner arrangements are intended to support development without immediate shareholder dilution.

What commercial opportunity size did Jaguar reference for short bowel syndrome and IF?

Jaguar referenced an estimated $8.0 billion global market for short bowel syndrome including IF by 2033. According to the company, that market estimate frames the potential long-term opportunity for therapies addressing IF.

What clinical and commercialization goals did Jaguar (JAGX) emphasize for crofelemer in MVID?

Jaguar emphasized demonstrating crofelemer effectiveness and achieving faster commercialization to meet healthcare delivery objectives for IF. According to the company, progress includes clinical milestones and plans to leverage AI and regulatory pathways to accelerate access.